Trials / Unknown
UnknownNCT04026100
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Clinical Trial of CTA101 UCART Cells Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CTA101 | Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6). |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2022-08-31
- Completion
- 2022-12-31
- First posted
- 2019-07-19
- Last updated
- 2019-10-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04026100. Inclusion in this directory is not an endorsement.